Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease.
about
Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brainsTherapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease.Meta-Analysis of Transcriptome Data Related to Hippocampus Biopsies and iPSC-Derived Neuronal Cells from Alzheimer's Disease Patients Reveals an Association with FOXA1 and FOXA2 Gene Regulatory Networks.Targeting iron metabolism in drug discovery and deliveryTranscriptomics of maternal and fetal membranes can discriminate between gestational-age matched preterm neonates with and without cognitive impairment diagnosed at 18-24 months.Neuropathology of SUDEP: Role of inflammation, blood-brain barrier impairment, and hypoxia.Drug Trafficking into Macrophages via the Endocytotic Receptor CD163.Molecular changes in the postmortem parkinsonian brain.Splitting the "Unsplittable": Dissecting Resident and Infiltrating Macrophages in Experimental Autoimmune Encephalomyelitis.α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration.Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review.OMIP-041: Optimized multicolor immunofluorescence panel rat microglial staining protocol.Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu-Hakola disease: lesion staging and dynamic changes of axons and microglial subsets.Role of Macrophages in Brain Tumor Growth and Progression.Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease
P2860
Q26796857-5F61DE73-60B9-493B-AA0B-97D8481857FEQ27303708-3E098EBC-BFB7-4753-8FC1-C52BB0AA8858Q31047629-8E04763D-0D60-43E0-9926-B7F16A3ECEE0Q33757232-7B395BD0-7B5B-48D5-992A-A2292491766CQ35231766-62558871-91CA-4BDA-902C-5E2FF4AE2F48Q37638367-6CE9FCEC-45B2-422C-A41E-06F617AC1777Q38537751-3FD0E3EB-9CFA-42FE-8F21-5ADAAF2E4714Q38887346-B5AED8F2-FF45-4E8C-BB76-6718F71E9CF7Q47118345-62A11735-2B1E-4B74-9E07-3BC2B8789AA7Q47127566-F22F3F34-85B9-4EB9-9FCC-D6F97AC386EDQ47920956-6DCDC9E7-CC2B-4DB5-8C58-36DA1B30E097Q48019386-8B51EF8F-AC8C-4C50-A9A1-BF0C1090208EQ48523519-B3A1311A-D685-4F00-B6CE-625FFE7B0579Q52628012-3205168B-AC5E-4552-9766-26F41B84FD12Q58773068-0BCCBEB5-7A76-48B0-8540-A76FDF52CCA8
P2860
Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phenotypic profile of alternat ...... mer's and Parkinson's disease.
@en
Phenotypic profile of alternat ...... mer's and Parkinson's disease.
@nl
type
label
Phenotypic profile of alternat ...... mer's and Parkinson's disease.
@en
Phenotypic profile of alternat ...... mer's and Parkinson's disease.
@nl
prefLabel
Phenotypic profile of alternat ...... mer's and Parkinson's disease.
@en
Phenotypic profile of alternat ...... mer's and Parkinson's disease.
@nl
P2093
P2860
P356
P1476
Phenotypic profile of alternat ...... mer's and Parkinson's disease.
@en
P2093
Michail E Kalaitzakis
Peixuan Pey
Ronald K B Pearce
Steve M Gentleman
W Sue T Griffin
P2860
P2888
P356
10.1186/2051-5960-2-21
P577
2014-02-14T00:00:00Z
P5875
P6179
1022524510